431 related articles for article (PubMed ID: 20446853)
21. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.
Gridelli C; Brodowicz T; Langer CJ; Peterson P; Islam M; Guba SC; Moore P; Visseren-Grul CM; Scagliotti G
Clin Lung Cancer; 2012 Sep; 13(5):340-6. PubMed ID: 22266043
[TBL] [Abstract][Full Text] [Related]
22. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
[TBL] [Abstract][Full Text] [Related]
25. Pemetrexed and maintenance therapy for non-small cell lung cancer.
Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
[No Abstract] [Full Text] [Related]
26. [Pemetrexed monotherapy in previously treated patients with advanced non small cell lung cancer; differences by histology. Our experience].
Pistillucci G; Sciacca V; Ciorra A; Di Palma T; Calabretta F; Lugini A; Rossi R; D'Aprile M; Veltri E
Recenti Prog Med; 2012 Feb; 103(2):62-5. PubMed ID: 22430749
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
Jones RJ; Twelves CJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
[TBL] [Abstract][Full Text] [Related]
28. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
Chouaid C; Nathan F; Pemberton K; Morris T
Cancer Chemother Pharmacol; 2011 May; 67(5):1203-8. PubMed ID: 21153822
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
[TBL] [Abstract][Full Text] [Related]
30. Pemetrexed for the treatment of non-small cell lung cancer.
Genova C; Rijavec E; Truini A; Coco S; Sini C; Barletta G; Dal Bello MG; Alama A; Savarino G; Pronzato P; Boccardo F; Grossi F
Expert Opin Pharmacother; 2013 Aug; 14(11):1545-58. PubMed ID: 23683110
[TBL] [Abstract][Full Text] [Related]
31. Antimetabolites in the management of non-small cell lung cancer.
Budde LS; Hanna NH
Curr Treat Options Oncol; 2005 Jan; 6(1):83-93. PubMed ID: 15610718
[TBL] [Abstract][Full Text] [Related]
32. [Pemetrexed].
Sudoh J; Gemma A
Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
[TBL] [Abstract][Full Text] [Related]
33. Pemetrexed therapy for malignant pleural mesothelioma.
Puto K; Garey JS
Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
[TBL] [Abstract][Full Text] [Related]
34. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
Villela LR; Stanford BL; Shah SR
Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
[TBL] [Abstract][Full Text] [Related]
35. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.
Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T
Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed: a novel antifolate agent enters clinical practice.
Kut V; Patel JD; Argiris A
Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
[TBL] [Abstract][Full Text] [Related]
37. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Custodio A; de Castro J
Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
[TBL] [Abstract][Full Text] [Related]
38. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
[TBL] [Abstract][Full Text] [Related]
39. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer.
Bearz A; Garassino I; Tiseo M; Caffo O; Soto-Parra H; Boccalon M; Talamini R; Santoro A; Bartolotti M; Murgia V; Berretta M; Tirelli U
Lung Cancer; 2010 May; 68(2):264-8. PubMed ID: 19632738
[TBL] [Abstract][Full Text] [Related]
40. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
